1. Dual antiplatelet therapy in patients with cirrhosis and acute myocardial infarction – A 13-year nationwide cohort study.
- Author
-
Wu, Victor Chien-Chia, Chen, Shao-Wei, Chou, An-Hsun, Ting, Pei-Chi, Chang, Chih-Hsiang, Wu, Michael, Hsieh, Ming-Jer, Wang, Chao-Yung, Chang, Shang-Hung, Lin, Ming-Shyan, Hung, Kuo-Chun, Hsieh, I-Chang, Chu, Pao-Hsien, Wu, Cheng-Shyong, and Lin, Yu-Sheng
- Subjects
- *
MYOCARDIAL infarction , *DRUG-eluting stents , *DRUG information materials , *NATIONAL health insurance , *ELECTRONIC health records , *CIRRHOSIS of the liver , *COHORT analysis , *LIVER transplantation - Abstract
Background: Patients with cirrhosis and acute myocardial infarction (AMI) present dilemma whether dual antiplatelet therapy (DAPT) should be used. Methods: Electronic medical records between 2001–2013 were retrieved from Taiwan National Health Insurance Research Database. Patients were excluded for missing information, age <20 years old, history of AMI, liver transplant, autoimmune disease, coagulopathy, taking DAPT 3 months before index date, follow-up <3 months, anticoagulation user, without DAPT, and events of myocardial infarction (MI), ischemic stroke, major bleeding, and heart failure within 3-month of enrollment. Primary outcomes were 1-year all-cause mortality, recurrent MI, major bleeding, and gastrointestinal bleeding. Results: A total of 150,887 patients with AMI retrieved. After exclusion criteria and propensity score-matching, 914 cirrhotic and 3,656 non-cirrhotic patients with AMI on DAPT were studied. During 1-year follow-up, there was significantly increased mortality in cirrhotic patients compared to non-cirrhotic patients (HR = 1.49, 95% CI = 1.28–1.74). There was significantly decreased recurrent MI in cirrhotic patients compared to non-cirrhotic patients (subdistribution HR [SHR] = 0.71, 95% CI = 0.54–0.92). However, non-significantly increased major bleeding (SHR = 1.23, 95% CI = 0.87–1.73) and significantly increased gastrointestinal bleeding (SHR = 1.49, 95% CI = 1.31–1.70). Conclusions: In cirrhotic patients with AMI, DAPT offers benefit with decreased recurrent MI at the expense of increased gastrointestinal bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF